Professional
Added to YB: 2025-06-09
Pitch date: 2025-03-31
HALO [neutral]
Halozyme Therapeutics, Inc.
+12.46%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Market Cap
$9.3B
Pitch Price
$64.06
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.38
P/E
16.77
EV/Sales
8.19
Sector
Biotechnology
Category
growth
Show full summary:
Macquarie Small Cap Core Fund Portfolio Holding: Halozyme Therapeutics, Inc.
HALO (holding update): Licenses Enhanze tech to convert IV drugs to subcutaneous injections, improving patient convenience & extending partner drug exclusivity. 4Q24 results beat consensus with royalties & adj EBITDA exceeding guidance. 2025 guidance & longer-term outlook (2026-28) reiterated.